🔎 Trials Near Me

Dachaigh › Myeloma iomaill › Oregon › Portland

Sgrùdaidhean clionaigeach Myeloma iomaill ann an Portland, OR

Tha 13 sgrùdaidhean airson Myeloma iomaill a’ lorg phàirtichean aig làraichean ann agus timcheall air Portland (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.

Teacsa sgrùdaidh oifigeil (Beurla)

A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

A’ fastadhÌre 3
  • Oregon Health And Science University, Portland
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07258511

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

A’ fastadhSgrùdadh amharc
  • OHSU Knight Cancer Institute, Portland
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT06784167

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

A’ fastadhÌre 2
  • Providence Health & Services, Portland
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT02693535

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

A’ fastadhÌre 2
  • Oregon Health and Science University, Portland
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT06297226

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

A’ fastadhÌre 1/2
  • Oregon Health and Science University /ID# 272282, Portland
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT06953960

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

A’ fastadhÌre 1
  • Providence Portland Medical Center, Portland
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Lùna 2026 · NCT07075185

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

A’ fastadhÌre 3
  • Research Site, Portland
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Lùna 2026 · NCT07764978

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

A’ fastadhÌre 2
  • Oregon Health & Science University, Portland
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Iuch 2026 · NCT05469893

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

A’ fastadhÌre 3
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Providence Willamette Falls Medical Center, Oregon City · 12 mìle air falbh
Gach aois · Gach gnè · Air ùrachadh 10 Ògmh 2026 · NCT05561387

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

A’ fastadhÌre 1/2
  • Oregon Health and Science University (OHSU) Marquam Hill Campus, Portland
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 20 Gibl 2026 · NCT03761108

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

A’ fastadhSgrùdadh amharc
  • Local Institution - 0016, Portland
Gach aois · Gach gnè · Air ùrachadh 22 Faoi 2026 · NCT06357754

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
  • Oregon Health Sciences University, Portland
Aoisean 40 agus nas sine · Gach gnè · Air ùrachadh 20 Faoi 2026 · NCT05366881

Sgrùdaidhean Myeloma iomaill ann am bailtean eile

Sgrùdaidhean eile ann an Portland

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.